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Odensvik K, Grave K, Greko C: Antibacterial drugs prescribed for dogs and cats
in Sweden and Norway 1990-1998. Acta vet. scand. 2001, 42, 189-198. – The usage
of veterinary antibacterial drugs in dogs and cats in Sweden and Norway for the period
1990-1998 was investigated by use of drug wholesalers´ statistics. Additionally, usage
of human antibacterial drugs in these species in Sweden was investigated by use of pre-
scription data for the period 1996-1998. On average, more than 50% of the prescribed
veterinary antibacterials in Sweden were beta-lactam antibiotics. In Norway, about 75%
of the preparations prescribed for dogs and cats contained sulfonamides and trimetho-
prim. Furthermore, the prescription data from Sweden showed a reduced usage of hu-
man antibacterials prescribed for dogs and cats since the beginning of the 1980s. Ap-
proximately 20% of the prescribed packages for dogs in the years 1996-1998 were
human approved drugs. The corresponding figure for cats was 13%. The differences
between the countries in the choice of antibacterial drugs can be explained by differ-
ences in the availability of approved preparations during the study period. The consump-
tion of veterinary antibacterials in dogs and cats in Sweden during the period was in the
range of 3% to 8% of the total use of veterinary antibacterials. The corresponding fig-
ures in Norway were in the range of 3% to 7%. It is of vital importance to study usage
patterns of antibacterial drugs in dogs and cats in surveillance and control of bacterial
resistance, but also in discussions of therapeutic appropriateness. Therefore, further re-
search is needed in this area.
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Introduction
The major route of transmission of resistant
bacteria or genes from animals to humans is
thought to be via the food chain (Witte 1996).
Published drug statistics have therefore focused
on antibacterial drug use in food producing an-
imals because of the fear of food-borne trans-
mission of antibacterial drug resistant organ-
isms to humans and the resulting human health
implications. However, because companion
small animals, i.e. dogs and cats, live in close
contact with their owners, the potential for
transmission of resistant bacteria to humans
and of resistance genes to human commensals
and pathogenes should not be overlooked.
Therefore, information about the consumption
of antibacterial drugs in companion small ani-
mals should be included in assessing the risk of
the spread of bacterial resistance.
Information on the choice and usage of antibac-
terials is also of interest from a clinical view-
point in terms of efficacy, appropriateness and
limiting the development of resistance in vete-
rinary pathogenes, and might initiate therapy
discussions both nationally and internationally. 
In comparison with most other countries, Swe-
den and Norway have the advantage of having
access to overall sales statistics of veterinary
drugs from the national drug wholesalers. In
addition, detailed veterinary prescription data
have been available in Sweden since 1996. Such
data can be utilised to interpret the wholesalers´
figures.
The main aims of the present study were to es-
timate the usage and analyse trends in the usage
pattern of antibacterial drugs in dogs and cats in
Sweden and Norway during 1990-1998 by use
of wholesalers´ statistics. The usage pattern and
proportional usage in dogs and cats of human
antibacterial preparations in Sweden in the pe-
riod 1996-1998 were also investigated by use of
prescription data. 
Materials and methods
In both Sweden and Norway, all antibacterial
preparations used in animals are prescription
drugs. Moreover, drugs intended for use in ani-
mals have to be sold by pharmacies, which in
turn are supplied by authorised drug whole-
salers, 2 in Sweden and 3 in Norway. 
Wholesaler data 1990-1998
In both countries, wholesalers´ data have a very
high degree of completeness. This is explained
by the fact that the wholesalers represent the en-
tire drug distribution network (i.e. there are no
other sources of antibacterials for use or pre-
scription by veterinarians) and that all pharma-
ceutical companies use the wholesalers to dis-
tribute their products. 
In Norway, overall sales data from the Norwe-
gian drug wholesalers are collected by the state-
owned drug wholesaler Norwegian Medicinal
Depot AS on behalf of the Directorate of
Health. In Sweden, the corresponding data are
available from Apoteket AB (The National
Corporation of Swedish Pharmacies, Stock-
holm). Relevant data were collected from both
sources for the years 1990-1998. Because over-
all sales figures of drugs from wholesalers pro-
vide a good approximation of the prescribing of
these drugs, the terms usage patterns, use, us-
age and consumption are used synonymously
with sales figures in this paper.
Classification system
In Norway and Sweden, the Anatomical Thera-
peutic Chemical veterinary classification
system (ATCvet) is used to classify veterinary
medicinal products (Nordic Council on Medi-
cines 1999) and was the system employed in
this study.
All antibacterial veterinary preparations ap-
proved only for use in dogs and/or cats were in-
cluded in the study (ATCvet code = QJ01), thus
excluding otic, ophtalmic and topical prepara-
tions. However, only oral antibacterial prepara-
tions were recorded, because some injectable
antibacterial veterinary drugs approved for use
in dogs and/or cats are also approved for other
animal species and, therefore, their exact use
cannot be determined from the ATCvet system. 
“Veterinary” drugs are preparations approved
only for use in animals and have “vet” included
in their brand names. “Human” drugs are prep-
arations originally approved for use in humans,
but may also be approved for use in some ani-
mal species.
Unit of measurement
Annual sales figures, in kg and in number of
packages sold, for the preparations included in
this study were calculated based on sales fig-
ures collected from the wholesalers in both
countries for 1990-1998. 
Swedish prescription data 1996-1998
Both in Sweden and Norway, electronic records
of veterinary prescriptions, i.e. species, pre-
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scribed drug, strength, formulation, package
size, and number of packages dispensed, are
kept by the pharmacies as part of the dispensing
process. Moreover, since January 1st 1996, data
on all veterinary prescriptions dispensed in
Sweden have been recorded in a centralised
data system owned by Apoteket AB. It should
be emphasised that the information in the data-
base does not include the name either of the an-
imal owner or of the veterinarian, therefore,
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Table 1: The amounts, in kg active substance, of oral veterinary antibacterial drugs (QJ01) approved for use in
dogs and/or cats sold by wholesalers to pharmacies in Sweden in 1990-1998.
ATC-
Class of drug Active substances 1990 1991 1992 1993 1994 1995 1996 1997 1998
group
QJ01A Tetracyclines Doxycycline, 63 75 72 77 69 66 69 70 78
oxytetracycline




QJ01D Cephalosporins Cefadroxil, cefalexin - - - - - - - 53 133
QJ01E Sulfonamides + Sulfadiazine + 67 44 73 93 95 88 124 137 151 
trimethoprim trimethoprim
QJ01F Lincosamides Clindamycin - - 9 102 151 172 163 179 191
QJ01M Quinolones Enrofloxacin 9 15 18 21 28 30 34 35 39
QJ01R Macrolides + 
imidazoles
TOTALS 863 891 993 1408 1716 1613 1572 1582 1612
Table 2: The amounts, in kg active substance, of oral veterinary antibacterial drugs (QJ01) approved for use in
dogs and/or cats sold by wholesalers to pharmacies in Norway in 1990-1998.
ATC-
Class of drug Active substances 1990 1991 1992 1993 1994 1995 1996 1997 1998
group
QJ01A Tetracyclines Doxycycline - - - - - <1 <1 <1 <1








QJ01F Lincosamides Lincomycin 27 36 42 61 69 70 46 35 27
QJ01M Quinolones Enrofloxacin - - <1 2 3 4 4 4 5
QJ01R Macrolides + Spiramycin + - - - - - - 1 7 4 
imidazoles metronidazole
TOTALS 262 223 308 321 353 382 453 469 468
confidentiality is maintained. The proportional
usage of human approved antibacterial drugs in
dogs and cats was derived from the Apoteket
data system, number of packages being the unit
of measurement. A corresponding centralised




The amounts, in kg active substance, of oral
veterinary antibacterial drugs approved for use
in dogs and/or cats sold by wholesalers to phar-
macies in Sweden are presented in Table 1. The
corresponding data for Norway is shown in Ta-
ble 2. In Norway, the usage increased gradually
from 262 kg active substance in 1990 to 468 kg
in 1998. The figures for Sweden for the same
period were 863 kg and 1612 kg, the usage
peaking in 1994 with 1716 kg active substance.
Figs. 1 and 2 illustrate the number of packages
of veterinary oral antibacterials approved for
dogs and/or cats sold by wholesalers in Sweden
and Norway respectively for the period 1990-
1998. In both countries, the number of pack-
ages sold increased gradually during the study
period.
In Sweden, the beta-lactams (QJ01C) were the
main veterinary antibacterial drugs prescribed
during the study period, both when the figures
were expressed as kg active substance and as
number of packages. On a percentage basis, use
of veterinary beta-lactam antibacterials (kg)
fell from 84% in 1990 to 63% in 1998 (Table 1).
In number of packages, the proportional use of
beta-lactam antibiotics was ranged from 48% to
57% during 1990-1998, with the lowest use in
1998 (Fig. 1).
In Norway, combination preparations of sulfon-
amides and trimethoprim or baquiloprim
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Figure 1. Number of packages of veterinary oral
antibacterial drugs approved for dogs and/or cats sold
by the drug wholesalers to pharmacies in Sweden in
1990-1998.
Figure 2. Number of packages of veterinary oral
antibacterial drugs approved for dogs and/or cats sold
by the drug wholesalers to pharmacies in Norway in
1990-1998.
(QJ01E) were the main veterinary preparations
sold by the drug wholesalers during the study
period, both when measured as kg active sub-
stance and in number of packages. On a per-
centage basis, use (kg) of these combination
preparations for dogs and cats varied slightly
during the study period (range: 77%-90%) (Ta-
ble 2). In number of packages, the proportional
use of sulfonamides and trimethoprim or baqui-
loprim ranged between 64% to 79%, the high-
est figure being in 1998. 
During the 9-year study period, an increase was
observed in the number of approved veterinary
oral antibacterial preparations (brand names
and strengths) for dogs and/or cats in both Swe-
den and Norway (Table 3).
Prescription data
In Sweden, the number of prescriptions of vet-
erinary and human antibacterial drugs for use in
dogs was approximately 211000, 213000 and
226000, in 1996, 1997 and 1998, respectively.
For cats the corresponding figures were 72000,
72000 and 79000 prescriptions.
Furthermore, in Sweden the prescribing of hu-
man approved antibacterial drugs to dogs in the
years 1996-1998 was approximately 20% of all
antibacterial packages prescribed for dogs,
while the corresponding figure for cats was
13% (Table 4). The prescribing of human anti-
bacterial drugs in dogs and cats, split into
classes of substances, is shown in Table 5. For
both species, the most frequently prescribed hu-
man drugs were beta-lactam antibiotics. 
The average number of packages prescribed per
prescription of antibacterial drugs in Sweden
was found to be stable during 1996-1998. Num-
ber of packages of veterinary antibacterial
preparations per prescription for dogs was 1.3
for each year of the study period, while for hu-
man preparations this figure was 1.1. For cats
these figures were 1.2 and 1.0 respectively.
Discussion
In both countries, all antibacterial drugs are
prescription-only and must be dispensed
through pharmacies. The figures used in the
present study are based on annual sales of the
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Table 3: Number of substances or combinations of substances / number of veterinary antibacterial preparations
approved for oral use in dogs and/or cats in Sweden and Norway, respectively, in the period 1990-1998.
1990 1991 1992 1993 1994 1995 1996 1997 1998
Sweden 9/14 9/15 10/16 11/16 10/14 12/17 12/18 13/19 13/19
Norway 2/3 2/3 3/5 3/5 4/7 6/10 7/13 8/15 8/16
Table  4: The distribution (%) of prescribed packages of antibacterial drugs to dogs and cats in Sweden, split
into human drugs (J01) and veterinary drugs (QJ01), in 1996-1998. J01 = General antiinfectives for systemic use
in humans; QJ01 = General antiinfectives for systemic use in animals.
Dogs Cats
1996 1997 1998 1996 1997 1998
Human preparations (J01) 21 20 19 13 12 13 
Veterinary preparations (QJ01) 79 80 81 87 88 87 
TOTALS 100 100 100 100 100 100
antibacterial drugs from national drug whole-
salers to pharmacies. The pharmacies stock
drugs on a short-term basis. Thus, annual sales
figures are reasonable estimates of the con-
sumption of the drugs in each of the years.
Wholesaler data
The use of wholesaler statistics to investigate
the use of antibacterial drugs in animals has
certain limitations. In both countries, a selec-
tion of antibacterial drugs, which are approved
for human use, are also approved for use in dogs
and cats. However, wholesalers´ statistics can-
not differentiate whether or not these drugs are
sold for use in humans or animals. Conse-
quently, these drugs are included in the whole-
salers´ statistics of drugs for human use. Pre-
scription data are necessary when monitoring
the extent of usage of human antibacterials for
use in dogs and cats and extra-label use of hu-
man approved antibacterials not approved for
use in dogs and cats.
Injectable veterinary preparations approved for
use in dogs and cats in Sweden and Norway are
approved for other animal species as well. It is
not possible to estimate the use of such drugs in
dogs and cats by use of wholesalers´ statistics.
Injectable antibacterial drugs are almost exclu-
sively administered in connection with the vet-
erinary consultation and are prescribed as ad
usum proprium preparations. Additionally, no
injectable preparations are prescribed to outpa-
tients. Therefore, these drugs are not identified
as prescribed to specific species within the cen-
tralised database of Apoteket AB. It is, how-
ever, thought that the use of injectable antibac-
terial drugs in dogs and cats is proportionally
small compared to oral use. 
Population size
When interpreting the usage of antibacterial
preparations in dogs and cats, it is necessary to
have an approximate knowledge of the popula-
tion size of the species of concern. The popula-
tion of dogs in Sweden increased from 700 000
in 1990 to 800 000 dogs in 1998; the cat popu-
lation declined from 1.1 million in 1990 to 1
million cats in 1998 (Moore 1991, Hedhammar
et al. 1999). In Norway, the population of dogs
has been roughly estimated to 400 000 and the
cat population to 300 000 (Personal communi-
cation, W. Bredal), however, these figures
should be interpreted with caution. 
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Table 5: Human antibacterial drugs (J01) prescribed for dogs and cats in Sweden during 1996-1998. The
figures represent the number of packages dispensed.
ATC-
Dogs Cats
group Class of drugs 1996 1997 1998 1996 1997 1998
J01A Tetracyclines 10 583 8 996 9 696 1 120 1 248 1 218
J01B Amphenicols 2 2 1 0 0 0
J01C Beta-lactam antibiotics 18 804 16 953 17 296 7 906 6 740 9 225
J01D Cephalosporins 14 296 17 504 19 417 267 327 378
J01E Sulfonamides + trimethoprim 4 707 3 951 3 277 158 163 164
J01F Macrolides and lincosamides 9 293 7 135 4 358 926 1 023 1 234
J01G Aminoglycosides 18 10 12 2 12 2
J01M Quinolones 211 186 192 2 1 1
J01X Others* 42 42 58 8 4 12
TOTALS 57 956 54 779 54 307 10 389 9 518 12 234
* includes e.g. fusidic acid
Human drugs
A cross-sectional prescription study performed
in Sweden in 1981 found that 36% and 39%, re-
spectively, of the packages of antibacterial
drugs prescribed for use in dogs and cats were
human drugs (Bingefors 1985). In the present
study it was found that 20% and 13%, respec-
tively, of the total number of prescribed pack-
ages of antibacterials for systemic use (i.e. ex-
cluding otic, ophtalmic and topical pre-
parations) in dogs and cats in Sweden in the pe-
riod 1996-1998, were human preparations.
During the period 1990-1998, the number of
veterinary antibacterial drug preparations
(brand names and strengths) approved in Swe-
den increased gradually. This likely accounts
for the substantial decrease in the usage of hu-
man drugs in dogs and cats in Sweden since the
early 1980s. 
A cross-sectional prescription study performed
in Norway in 1987-1988 found that 60% and
70% of prescriptions of antibacterial drugs pre-
scribed for use in dogs and cats respectively
were human approved drugs (Grave et al.
1992). This can easily be explained by the fact
that at that time only 3 oral veterinary antibac-
terial preparations (brand names and strengths)
were approved for use in dogs and cats. Since
1988, the number of approved veterinary anti-
bacterial preparations has increased from 3 to
16. The use of human antibacterial drugs in
dogs and cats is thus thought to be much lower
in 1998 than in 1987-1988. However, in order to
accurately estimate the usage of human anti-
bacterial drugs in Norway a centralised data-
base is needed.
The differences in the type and number of vete-
rinary antibacterials approved for dogs and cats
in Sweden and Norway may, in part, explain the
differences in the usage patterns between the 2
countries. The number of substances and vete-
rinary antibacterial preparations (brand names
and strengths) approved for dogs and cats in
Norway was lower than in Sweden during the
study period. For example, veterinary prepara-
tions containing cephalosporins, ampicillin or
phenoxymethylpenicillin are approved for dogs
and/or cats in Sweden, but not in Norway. The
veterinarians in Norway thus have to prescribe
a human approved product when they want an
equivalent antibacterial. 
Units of measurements
In the present study, sales figures were pre-
sented as kg active substance. Antibacterial
drugs are used in different dosages depending
on their potency, rate of absorption, and the size
of the animal in question. Therefore, sales fig-
ures of antibacterial drugs given as kg active
substances must be interpreted with caution
when the aim is to analyse prescription patterns
of these drugs. 
To correct for the differences in dosages when
interpreting drug sales statistics, defined daily
dose (DDD) is used in human medicine as a
unit of measurement (Capellà 1993, WHO
1998). This unit of measurement allows for
comparison of drug use in a medical context.
DDD is defined as the assumed average mainte-
nance dose per day for the drug used in its main
indication in adults. DDD is considered as the
“gold standard” in drug consumption studies
(Capellà 1993, WHO 1998). Unfortunately, the
number of DDD prescribed for dog cannot eas-
ily be estimated based on sales statistics, be-
cause of the wide range of weights, especially
of dogs «at risk» of being treated with an anti-
bacterial drug.
However, sales statistics, expressed as kg active
substance, may be utilised to estimate the con-
tribution of use in dogs and cats of veterinary
antibacterial drugs to the total use of these
drugs. In 1990, overall sales of veterinary anti-
bacterial drugs for therapeutic use in Sweden
was 30.3 tonnes active substance. This figure
declined to 19.3 tonnes in 1998 (Odensvik &
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Greko 1998, Odensvik 1999). Sales figures (kg)
in Sweden, of veterinary antibacterials ap-
proved only for dogs and cats, increased from
3% of the total use in 1990 to 8% in 1998. 
In Norway, overall sales figures of veterinary
antibacterials for therapeutic use decreased
from 9.5 tonnes in 1990 to 6.8 tonnes in 1998
(Grave & Rønning 1997, 1998, 1999). During
the same period, the usage of veterinary anti-
bacterials for dogs and cats, as a percentage of
all veterinary antibacterials, increased from 3%
to 7%. 
The policies taken to promote prudent use of
antibacterials, especially in food producing an-
imals, may have contributed to the total de-
crease seen in both countries in the consump-
tion of antibacterials prescribed to animals.
As a comparison, in Norway, consumption of
antibacterial drugs in human medicine was es-
timated to be 35 tonnes both in 1992 and in
1996 (Grave et al. 1999). Therefore, the contri-
bution to the total environmental load in Nor-
way of use of antibacterial drugs in dogs and
cats is proportionally small. Corresponding
consumption data for antibacterial drug use in
human medicine in Sweden is not published.
Consideration of the use of antibacterial drugs
in terms of sold packages may give a more pre-
cise idea of the prescribing patterns than kg ac-
tive substance (Capellà 1993). This is espe-
cially true when the number of packages
prescribed per treatment is thought to be con-
stant for specific groups of diseases, e.g. infec-
tious diseases. In the present study, it was found
that in Sweden number of packages per pre-
scriptions of veterinary antibacterial drugs for
dogs and cats remained constant from 1996 to
1998. Based on information about the package
size and the recommended dosage regimen for
veterinary preparations approved for dogs and
cats in Norway (Tørisen 1990, 1992, 1994,
1996, 1998) it is reasonable to believe that this
is true for Norway as well. 
Usage pattern
The usage in dogs and cats in Sweden, meas-
ured by the number of sold packages, was
mainly beta-lactam antibacterials during 1990-
1998. The number of packages sold of sulfona-
mides in combination with trimethoprim, lin-
cosamides (i.e. clindamycin) and quinolones
(i.e. enrofloxacin) increased during the period.
In contrast to Norway, Sweden had no approved
preparation in the ATCvet group QJ01R i.e.
spiramycin in combination with metronidazole.
In Norway, the principle antibacterial drugs
used during the study period, measured as num-
ber of packages sold, were trimethoprim in
combination with sulfonamides (QJ01E). The
beta-lactam antibacterials (QJ01C) were ap-
proved in Norway as veterinary preparations
for the first time in 1994 and the number of
packages sold of this group has since then in-
creased, while the use of lincosamides has de-
creased.
In the present study it was found that the usage
of human and veterinary antibacterial drugs for
dogs and cats in Sweden during the period
1996-1998 increased only slightly. However,
the number of animals “at risk” also increased
slightly during the period, suggesting that the
use of antibacterials in dogs and cats remained
relatively constant on a per animal basis.
In Norway, the number of packages sold of vet-
erinary antibacterial drugs for dogs and/or cats
almost doubled during the study period. As we
do not have information about the consumption
of human antibacterial drugs by dogs and cats
we cannot conclude whether or not the inci-
dence of treatment of bacterial diseases has in-
creased in Norway. The data presented in the
present study only gives information of the
trends of use of veterinary antibacterial drugs.
In addition to the previously discussed need for
a centralised database like the one in Sweden,
reliable statistics about the number of dogs and
cats at risk of being treated in Norway are nec-
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essary to estimate the incidence of treatment
with antibacterial drugs.
Bacterial resistance
In the efforts to contain antibacterial drug resis-
tance, both from the veterinary and human pub-
lic health viewpoints, joint monitoring of use
and resistance is a crucial component. In the
present study, an increase in sales of lincosa-
mides for veterinary use was noted in both Swe-
den and Norway. Interestingly, a parallel in-
crease in resistance to lincosamides in
staphylococci isolated from pyoderma in dogs
has been reported from both countries (Kruse et
al. 1996, Hansson et al. 1997, Holm et al.
1997). However, the observation should be
interpreted with caution, as data on sales of hu-
man lincosamides and macrolides are not avail-
able for the whole period of observation. None-
theless, information of this type is needed as a
basis for discussions about current prescription
policies and practices. If interventions designed
to change antibacterial drug use behaviour are
implemented, baseline data on use and resis-
tance will be essential for evaluations of the ef-
fectiveness of those interventions. 
It is crucial to be able to study prescription/us-
age patterns of antibacterial drugs in dogs and
cats not only in the surveillance of bacterial re-
sistance, but also in discussions of the therapeu-
tic appropriateness. Therefore, further research
is needed in the area. Moreover, information
about the frequency of prescribing of human
drugs may encourage the pharmaceutical in-
dustry to apply for approval of human drugs as
veterinary drugs for companion small animals.
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Sammanfattning
Förskrivning av antibakteriella läkemedel till hun-
dar och katter i Sverige och Norge 1990-1998.
Förskrivningen av antibakteriella läkemedel till hun-
dar och katter under åren 1990 till 1998 undersöktes
med hjälp av försäljningsstatistik. Det svenska ma-
terialet innehöll även receptbaserad statistik uppdelat
på djurslag för åren 1996-1998. Studien visade att
mer än hälften av de i Sverige förskrivna antibakte-
riella medlen till hundar och katter utgjordes av beta-
laktamer. I Norge däremot dominerades förskriv-
ningen av sulfa-trimetopriminnehållande läkemedel
som utgjorde mer än 75%. Vidare sågs i det svenska
receptmaterialet att förskrivningen till hund och katt
av humanmedicinskt godkända antibakteriella medel
hade minskat i jämförelse med 1980-talets början.
Ungefär 20% av de förskrivna förpackningarna till
hund mellan 1996 och 1998 var humanläkemedel.
Motsvarande siffra för katt var 13%.
Skillnaden mellan Sverige och Norge avseende val
av antibakteriellt läkemedel kan bland annat
förklaras av olika tillgång på godkända läkemedel.
Förbrukningen av antibakteriella medel till hund och
katt varierande mellan 3%-8% av den totala antibak-
teriella förskrivningen till samtliga djurslag i Sve-
rige. Motsvarande siffror för Norge visades vara 3%-
7% under motsvarande period.
Att kunna följa förbrukningen av antibakteriella
läkemedel till hund och katt är viktigt, dels för
övervakning av resistensläget, dels för att kunna dis-
kutera adekvat terapi vid infektioner. Ytterligare
studier är därför önskvärda.
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